Gabapentin Tablet, Film Coated
Product Images NDC 68382-205

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68382-205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Tablets (22ce4ea0 1cf7 4364 878a D9e08f1934fd 01)

A mathematical formula panel showing the calculation of creatinine clearance (CLCr). The formula includes age in years, weight in kilograms, serum creatinine in mg/dL, and a gender adjustment factor of 0.85 for female patients.*

FDA Label Image

Gabapentin Tablets (22ce4ea0 1cf7 4364 878a D9e08f1934fd 02)

Chemical structure of gabapentin showing a cyclohexane ring attached to a carbon with amino (CH2NH2) and carboxyl (CH2CO2H) functional groups.*

FDA Label Image

Gabapentin Tablets (22ce4ea0 1cf7 4364 878a D9e08f1934fd 03)

A line graph showing mean pain scores over 8 weeks comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks from baseline to week 8, with indicators for a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decreasing pain score trend, while placebo remains relatively stable.*

FDA Label Image

Gabapentin Tablets (22ce4ea0 1cf7 4364 878a D9e08f1934fd 04)

A line graph depicting the mean pain score over seven weeks, comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis shows weeks from baseline to week 7, and the y-axis shows mean pain scores from 0 to 10. The chart indicates a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Gabapentin Tablets (22ce4ea0 1cf7 4364 878a D9e08f1934fd 05)

A bar chart comparing percentages in two studies labeled Study 1 and Study 2. Each study compares placebo (PBO) responses with Gabapentin (GBP) doses: 3600 mg in Study 1, and 1800 mg and 2400 mg in Study 2. Statistical significance markers indicate p-values below 0.01 and 0.001 for some comparisons, with percentages noted above each bar.*

FDA Label Image

Gabapentin Tablets (22ce4ea0 1cf7 4364 878a D9e08f1934fd 06)

A scatter plot chart showing the percentage difference versus daily dose of Gabapentin (mg). The x-axis represents daily doses from 600 to 1800 mg, and the y-axis shows the difference in percentage from 2% to 22%. The plot compares results from three studies labeled as Study a (black squares), Study b (gray squares), and Study c (white squares) with corresponding markers at various dose points.*

FDA Label Image

Gabapentin Tablets (22ce4ea0 1cf7 4364 878a D9e08f1934fd 07)

Label for Gabapentin Tablets USP 600 mg oral film-coated tablets by Zydus Pharmaceuticals USA Inc. The package contains 100 tablets. The label includes dosage information, storage instructions, child-resistant packaging notice, and distributor details for Zydus Pharmaceuticals (USA) Inc.*

FDA Label Image

Gabapentin Tablets (22ce4ea0 1cf7 4364 878a D9e08f1934fd 08)

Gabapentin Tablets, USP 800 mg oral film-coated tablets by Zydus Pharmaceuticals USA Inc. The label indicates 100 tablets in the package, prescription only. It includes dosing and storage information, child-resistant packaging notice, and manufacturer details for Zydus Lifesciences Ltd., Ahmedabad, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.